Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 64

1.

Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided?

Warnke C, Menge T, Hartung HP, Racke MK, Cravens PD, Bennett JL, Frohman EM, Greenberg BM, Zamvil SS, Gold R, Hemmer B, Kieseier BC, Stüve O.

Arch Neurol. 2010 Aug;67(8):923-30. doi: 10.1001/archneurol.2010.161. Review.

3.

The link between VLA-4 and JC virus reactivation.

Monaco MC, Major EO.

Expert Rev Clin Immunol. 2012 Jan;8(1):63-72. doi: 10.1586/eci.11.85. Review.

PMID:
22149341
4.

Therapeutic uses of anti-α4-integrin (anti-VLA-4) antibodies in multiple sclerosis.

Schwab N, Schneider-Hohendorf T, Wiendl H.

Int Immunol. 2015 Jan;27(1):47-53. doi: 10.1093/intimm/dxu096. Epub 2014 Oct 17. Review.

PMID:
25326459
5.

Progressive multifocal leukoencephalopathy and natalizumab.

Hellwig K, Gold R.

J Neurol. 2011 Nov;258(11):1920-8. doi: 10.1007/s00415-011-6116-8. Epub 2011 Jun 7. Review.

PMID:
21647730
6.

Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.

Bartt RE.

Curr Opin Neurol. 2006 Aug;19(4):341-9. Review.

PMID:
16914971
7.

Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions.

Stüve O, Marra CM, Cravens PD, Singh MP, Hu W, Lovett-Racke A, Monson NL, Phillips JT, Tervaert JW, Nash RA, Hartung HP, Kieseier BC, Racke MM, Frohman EM, Hemmer B.

Arch Neurol. 2007 Feb;64(2):169-76. Review.

PMID:
17296831
8.

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.

Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, Nath A.

Lancet Neurol. 2010 Apr;9(4):438-46. doi: 10.1016/S1474-4422(10)70028-4. Review. Erratum in: Lancet Neurol. 2010 May;9(5):463. DeLuca, Andrea [corrected to De Luca, Andrea].

PMID:
20298967
9.
10.

Natalizumab (Tysabri) treatment for relapsing multiple sclerosis.

Johnson KP.

Neurologist. 2007 Jul;13(4):182-7. Review.

PMID:
17622909
11.

Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab.

Sørensen PS, Bertolotto A, Edan G, Giovannoni G, Gold R, Havrdova E, Kappos L, Kieseier BC, Montalban X, Olsson T.

Mult Scler. 2012 Feb;18(2):143-52. doi: 10.1177/1352458511435105. Review.

PMID:
22312009
12.

Reactivation of JC virus and development of PML in patients with multiple sclerosis.

Khalili K, White MK, Lublin F, Ferrante P, Berger JR.

Neurology. 2007 Mar 27;68(13):985-90. Review.

PMID:
17389301
13.

Natalizumab therapy for multiple sclerosis.

Derfuss T, Kuhle J, Lindberg R, Kappos L.

Semin Neurol. 2013 Feb;33(1):26-36. doi: 10.1055/s-0033-1343793. Epub 2013 May 25. Review.

PMID:
23709210
14.

Review of progressive multifocal leukoencephalopathy and natalizumab.

Aksamit AJ.

Neurologist. 2006 Nov;12(6):293-8. Review.

PMID:
17122725
15.

"Thinking without thinking" about natalizumab and PML.

Ransohoff RM.

J Neurol Sci. 2007 Aug 15;259(1-2):50-2. Epub 2007 May 22. Review.

PMID:
17521672
16.

[[Natalizumab therapy, 2013].

Karácsony M, Bencsik K, Vécsei L.

Ideggyogy Sz. 2014 Jul 30;67(7-8):220-8. Review. Hungarian.

PMID:
25509362
17.

The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy.

Wattjes MP, Richert ND, Killestein J, de Vos M, Sanchez E, Snaebjornsson P, Cadavid D, Barkhof F.

Mult Scler. 2013 Dec;19(14):1826-40. doi: 10.1177/1352458513510224. Epub 2013 Nov 5. Review.

PMID:
24192217
18.
19.

Progressive multifocal leukoencephalopathy: lessons from AIDS and natalizumab.

Berger JR, Houff S.

Neurol Res. 2006 Apr;28(3):299-305. Review.

PMID:
16687057
20.

Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring.

Hunt D, Giovannoni G.

Pract Neurol. 2012 Feb;12(1):25-35. doi: 10.1136/practneurol-2011-000092. Review.

PMID:
22258169

Supplemental Content

Support Center